Vaginal progesterone to prevent spontaneous preterm birth in women with a sonographic short cervix: The story of the PREGNANT trial
Document Type
Article (peer-reviewed)
Publication Date
6-1-2024
Abstract
The PREGNANT trial was a randomized, placebo-controlled, multicenter trial designed to determine the efficacy and safety of vaginal progesterone (VP) to reduce the risk of birth < 33 weeks and of neonatal complications in women with a sonographic short cervix (10 to 20 mm) in the mid-trimester (19 to 23 6/7 wk). Patients allocated to receive VP had a 45% lower rate of preterm birth (8.9% vs 16.1%; relative risk = 0.55; 95% CI: 0.33-0.92). Neonates born to mothers allocated to VP had a 60% reduction in the rate of respiratory distress syndrome. This article reviews the background, design, execution, interpretation, and impact of the PREGNANT Trial.
Recommended Citation
Romero, Roberto, Arun Meyyazhagan, Sonia S. Hassan, George W. Creasy, and Agustin Conde-Agudelo. 2024. "Vaginal progesterone to prevent spontaneous preterm birth in women with a sonographic short cervix: The story of the PREGNANT trial," Clinical Obstetrics and Gynecology 67(2): 433–457.
DOI
10.1097/GRF.0000000000000867
Language
English
https://doi.org/10.1097/GRF.0000000000000867